New hope for breast cancer patients with brain spread: drug combo plus radiation under study

NCT ID NCT06016387

First seen Jan 31, 2026 · Last updated Apr 29, 2026 · Updated 9 times

Summary

This study is for people with a specific type of breast cancer (HER2-positive) that has spread to the lining of the brain and spinal cord. It tests whether adding a targeted drug combination (tucatinib, trastuzumab, and capecitabine) to radiation therapy can help control the disease and improve survival. About 30 participants will receive the treatment, and researchers will track how long they live and how long it takes for the cancer in the central nervous system to worsen.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HER2 POSITIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Sunnybrook Health Sciences Centre

    RECRUITING

    Toronto, Ontario, M4N 3M5, Canada

    Contact

    Contact Email: •••••@•••••

    Contact

    Contact Email: •••••@•••••

  • The Ottawa Hospital

    RECRUITING

    Ottawa, Ontario, Canada

    Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.